Inqovi (decitabine-cedazuridine)

Numéro de dossier de l’APP: 21608
État des négociations:
Under consideration for negotiation
Indication(s):
Inqovi (decitabine and cedazuridine) is indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System (IPSS) groups
Promoteur/fabricant:
Taiho Pharma Canada, Inc.
Numéro de projet de l’ACMTS:
PC0228-000
Lettre-contrat de l’APP:
Not Applicable
Conclusion du processus de négociation:
Not Applicable